TCG Lifesciences and Endo enter discovery alliance
This article was originally published in Scrip
TCG Lifesciences, a research services and informatics company, is collaborating with Endo Pharmaceuticals to discover novel small-molecule drug candidates for the treatment of pain. The tie-up will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of TCG's discovery research arm, Chembiotek. Endo will have full ownership of the compounds developed under the collaboration as well as exclusive global rights. It will also finance all subsequent drug development and commercialisation activities, provide research funding and make milestone payments to TCG. TCG is based in India and is part of The Chatterjee Group, an investment conglomerate headquartered in New York.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.